NovoCure Ltd. (NASDAQ:NVCR) rose 2.8% during trading on Tuesday . The stock traded as high as $7.85 and last traded at $7.79, with a volume of 293,863 shares trading hands. The stock had previously closed at $7.58.

NVCR has been the topic of several research reports. Deutsche Bank AG cut their price objective on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, July 29th. JMP Securities cut their price objective on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating on the stock in a research report on Friday, July 29th. Wedbush cut their price objective on shares of NovoCure from $30.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday, July 29th. JPMorgan Chase & Co. cut their price objective on shares of NovoCure from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, July 29th. Finally, Zacks Investment Research lowered shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. NovoCure has an average rating of “Hold” and an average price target of $21.43.

The stock’s market cap is $668.18 million. The firm has a 50-day moving average of $10.51 and a 200-day moving average of $12.24.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.11. The firm had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $15.90 million. Equities research analysts predict that NovoCure Ltd. will post ($1.80) earnings per share for the current fiscal year.

In related news, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total value of $244,800.00. Following the transaction, the chief operating officer now directly owns 324,084 shares of the company’s stock, valued at $3,966,788.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gert L. Perlhagen sold 676,576 shares of NovoCure stock in a transaction on Friday, August 5th. The stock was sold at an average price of $1.85, for a total transaction of $1,251,665.60. Following the completion of the transaction, the director now directly owns 676,576 shares in the company, valued at $1,251,665.60. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in NovoCure stock. Morgan Stanley bought a new stake in NovoCure Ltd. (NASDAQ:NVCR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 430,177 shares of the company’s stock, valued at approximately $9,619,000. Morgan Stanley owned 0.51% of NovoCure as of its most recent SEC filing.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.